Evidence map›Paper›PMID 28878320›Full record

ArticleScientific reports2017

A new mass spectrometry-based method for the quantification of histones in plasma from septic shock patients.

J L García-Giménez, C Romá-Mateo, N Carbonell, L Palacios, L Peiró-Chova, E García-López, M García-Simón, R Lahuerta, C Gimenez-Garzó, E Berenguer-Pascual and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Liquid Liver Biopsy for Disease Diagnosis and Prognosis.Journal of clinical and translational hepatology · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  14. Circulating Histones to Detect and Monitor the Progression of Cancer.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

J L García-GiménezCenter for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain. j.luis.garcia@uv.es.ORCID 0000-0001-7547-7872
C Romá-MateoCenter for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain.
N CarbonellINCLIVA Biomedical Research Institute, Valencia, Spain.
L PalaciosINCLIVA Biomedical Research Institute, Valencia, Spain.
L Peiró-ChovaINCLIVA Biomedical Research Institute, Valencia, Spain.
E García-LópezDepartment of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.
M García-SimónINCLIVA Biomedical Research Institute, Valencia, Spain.
R LahuertaINCLIVA Biomedical Research Institute, Valencia, Spain.
C Gimenez-GarzóDepartment of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.
E Berenguer-PascualDepartment of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.
M I MoraDepartment of Hepatology, Proteomics laboratory, CIMA, University of Navarra; Ciberhed; Idisna; PRB2, ProteoRed-ISCIII, Pamplona, Spain.
M L ValeroCentral Service for Experimental Research (SCSIE), University of Valencia, Burjassot, Spain.
A AlpízarProteomics Unit, Centro Nacional de Biotecnología (CSIC); PRB2, ProteoRed-ISCIII, Madrid, Spain.
F J CorralesProteomics Unit, Centro Nacional de Biotecnología (CSIC); PRB2, ProteoRed-ISCIII, Madrid, Spain.
J BlanquerINCLIVA Biomedical Research Institute, Valencia, Spain.
F V PallardóCenter for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain. federico.v.pallardo@uv.es.
Universitat de València · ESHospital Clínico Universitario de Valencia · ESCentro Nacional de Biotecnología · ESINCLIVA Health Research Institute · ESNavarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to develop a novel method to detect circulating histones H3 and H2B in plasma based on multiple reaction monitoring targeted mass spectrometry and a multiple reaction monitoring approach (MRM-MS) for its clinical application in critical bacteriaemic septic shock patients. Plasma samples from 17 septic shock patients with confirmed bacteraemia and 10 healthy controls were analysed by an MRM-MS method, which specifically detects presence of histones H3 and H2B. By an internal standard, it was possible to quantify the concentration of circulating histones in plasma, which were significantly higher in patients, and thus confirmed their potential as biomarkers for diagnosing septic shock. After comparing surviving patients and non-survivors, a correlation was found between higher levels of circulating histones and unfavourable outcome. Indeed, histone H3 proved a more efficient and sensitive biomarker for septic shock prognosis. In conclusion, these findings suggest the accuracy of the MRM-MS technique and stable isotope labelled peptides to detect and quantify circulating plasma histones H2B and H3. This method may be used for early septic shock diagnoses and for the prognosis of fatal outcomes.

Indexed as

BiomarkersMass SpectrometryAdolescentAdultAgedAged, 80 and overBacteremiaCase-Control StudiesHistonesHumansMiddle AgedPeptidesPrognosisROC CurveSeverity of Illness IndexShock, SepticBiomarkersHistonesPeptides

Identifiers

PMID28878320
PMCPMC5587716
OpenAlexW2753589803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.